Cargando…
Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
Tumour therapy with cyclophosphamide (CPA), an alkylating chemotherapeutic agent, has been associated with reduced tumour blood supply and antiangiogenic effects when applied in a continuous, low-dose metronomic schedule. Compared to conventional high-dose scheduling, metronomic CPA therapy exhibits...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828885/ https://www.ncbi.nlm.nih.gov/pubmed/18266977 http://dx.doi.org/10.1111/j.1582-4934.2008.00255.x |